The merger of Maxim Pharmaceuticals and EpiCept was completed on January 4, 2006. Maxim had been listed on the Stockholm Stock Exchange since October 24, 1997 and the final date for trading in Maxim shares on the Stockholm Stock Exchange´s O List was December 30, 2005. Maxim shareholders received new EpiCept Corporation shares in connection with the merger. Trading in the new merged company - EpiCept Corporation - commence on the Stockholm Stock Exchange´s O List tomorrow. Trading in EpiCept shares on NASDAQ in New York started on January 5.
EpiCept is a "specialty pharma" company. Following the merger with Maxim, the company has a research portfolio that includes Maxim´s cancer-treatment projects and EpiCept´s pain-relief projects.
"The fact that EpiCept can now be traded on the Stockholm Stock Exchange means a lot to those investors who received EpiCept shares in exchange for their Maxim shares. At present, these investors account for approximately 28 percent of the shares in the company, of which 15 percent will be traded on the Stockholm Stock Exchange. We look forward to helping EpiCept Corporation gain maximum benefits from the Nordic financial market," says Jenny Rosberg, President Company Services, OMX.
A round lot in EpiCept Corporation, whose short name is EPCT, amounts to 200 shares and the company is included in the Healthcare and Pharmaceuticals/Biotechnology sector.